Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.32 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.32 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.32 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.32 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.32 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.32 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.32 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640734 | 0.79 | NFE2L2 (0.31) | NFE2L2ATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL16684176 | 0.72 | — | — | |
| SCHEMBL11790919 | 0.72 | — | — | |
| SCHEMBL10066091 | 0.71 | NR1H4 (0.34) | — | |
| SCHEMBL4008383 | 0.65 | BACE1 (0.39) | — | |
| SCHEMBL12521535 | 0.61 | POLB (0.42) | — | |
| SCHEMBL38662545 | 0.60 | NFE2L2 (0.40) | NFE2L2 | |
| SCHEMBL16644803 | 0.57 | NR1H4 (0.36) | — | |
| SCHEMBL17866831 | 0.57 | — | — | |
| SCHEMBL10581556 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682111-B2 | Method for preventing or treating neurodegenerative diseases | SU WEIWEI (CN) | 2017-06-20 | — | — | US | disclosed |
| US-20160082059-A1 | METHOD FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | SU WEIWEI (CN) | 2016-03-24 | — | — | US | disclosed |
| US-20150105460-A1 | LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF | SU WEIWEI (CN) | 2015-04-16 | — | — | US | disclosed |
| EP-2857391-A1 | LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF | Sun Yat-Sen University (CN) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105460-A1 | LABDANE DITERPENOID COMPOUNDS, SEMEN BIOTAE EXTRACT, AND PREPARATION METHOD AND USE THEREOF | NASP, GSDMD, DRD5 | NFE2L2 1850/4885ATP1A1 3769/4885ATP1B1 3776/4885 |
| US-20160082059-A1 | METHOD FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | NFE2L2 830/4885ATP1A1 1451/4885ATP1B1 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.